Predictive Biosciences

Agilent Technologies of Santa Clara, Calif., has received US Patent No.

NEW YORK (GenomeWeb News) – Predictive Biosciences will offer its molecular diagnostic bladder cancer tests to Arup Laboratories' national network of clients under a deal announced today.

Thermo Fisher Scientific has been awarded US Patent No. 8,378,115, "Monomethine dyes."
Charles Brush, Jianqin Liu, Peter Czerney, and Matthias Wenzel are named as inventors.

A team led by researchers at the University of Southern California and University of Miami has developed a nine-protein panel for predicting the progression of bladder cancer.

SISCAPA Assay Technologies this week appointed Gustavo Salem to its board of directors and hired Ian Wright as a consultant and primary architect of diagnostic business strategy.

This story was originally published June 22.

Applied Proteomics announced this week that it has appointed Peter Klemm as CEO and James Blair to its board of directors.

BG Medicine this week appointed Eric Bouvier as president and CEO. He replaces Pieter Muntendam, who has moved to the role of executive vice president and chief medical officer.

By Adam Bonislawski
With DNA-based affinity agents gaining prominence as tools for protein capture, scientists and biotech firms are exploring biomarker assays that simultaneously report both genetic and proteomic data.

According to the company's earnings statement, MDxHealth's product and service revenues nearly doubled – from €1 million in 2009 to €2 million in 2010 – due to several companion diagnostics deals and biomarker licensing agreements inked with major drug companies.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.